
==== Front
Eur J Med Res
Eur J Med Res
European Journal of Medical Research
0949-2321
2047-783X
BioMed Central London

2054
10.1186/s40001-024-02054-5
Research
Fungi identified via next-generation sequencing in bronchoalveolar lavage fluid among patients with COVID-19: a retrospective study
Yang Xiaobo
Gao Xuehui
Zhang Hongling
Xu Jiqian
Shang You you_shanghust@163.com

grid.33199.31 0000 0004 0368 7223 Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
17 9 2024
17 9 2024
2024
29 46310 4 2024
8 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Background

The epidemiology of fungi identified via next-generation sequencing in bronchoalveolar lavage fluid among patients with COVID-19 is unknown.

Methods

De-identified information, including age, SARS-CoV-2 reads and fungi from bronchoalveolar lavage fluid, were used to analysis.

Results

A total of 960 patients with COVID-19 were included. Gender was unknown in 38 patients, and 648 (70.3%) of the rest patients were male. For 876 patients with information on age, their mean ± standard age was 63.4 ± 21.3 years, with the minimum being 0.2 years and the maximum being 101 years. For all the patients, their median [interquartile range] SARS-CoV-2 reads were 26,038 [4421.5, 44,641.5]. The Aspergilli were identified in 159 (16.6%) patients, with Aspergillus fumigatus, Aspergillus flavus and Aspergillus niger in 103 (10.7%), 81 (8.4%) and 17 (1.8%), respectively. The Mucoraceae were identified in 14 (1.5%) patients. Pneumocystis jirovecii was identified in 65 (6.8%) patients, among whom 12 (18.5%) patients also had Aspergilli. The Cryptococcaceae and the Dematiaceae were also identified in some patients, including Cryptococcus in 11 (1.1%) patients.

Conclusions

In bronchoalveolar lavage fluid among patients with COVID-19, the Aspergilli were very commonly identified, as were the Mucoraceae, Pneumocystis jirovecii and Cryptococcus via next-generation sequencing.

Keywords

Next-generation sequencing
Bronchoalveolar lavage fluid
COVID-19
Fungal infection
Aspergilli
Mucoraceae
Pneumocystis jirovecii
Cryptococcus
http://dx.doi.org/10.13039/501100012166 National Key Research and Development Program of China 2021YFC2500801 Yang Xiaobo issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcBackground

In patients with coronavirus disease 2019 (COVID-19), fungal co-infection is associated with a significant increase in morbidity and mortality, especially in critically ill patients in intensive care units (ICUs) [1]. Fungal co-infection was most commonly identified in respiratory tract and blood. The diagnosis of proven invasive pulmonary aspergillosis (IPA) and mucormycosis requires microbiologic or histopathologic evidence. The former is more commonly used and more feasible than the latter. However, a microbiologic examination is mainly based on culture, which is time-consuming and is of low sensitivity. Another microbiologic method is molecular analysis of DNA sequences of fungi in bronchoalveolar lavage fluid (BALF) [2]. As far as we know, limited information on DNA sequences of fungi in BALF among patients with COVID-19 is available. We aimed to fill this gap by conducting a retrospective study on fungi identified by next-generation sequencing (NGS) of pathogens in BALF among patients with COVID-19.

Methods

When caring for intubated patients with COVID-19, if superinfection including fungal infection is suspected and microbiologic culture is not sufficient to explain the condition or not efficient enough, treating physicians sometimes ask for the permission from a patient’s next of kin and provide demographic information and a BALF specimen to an NGS company. The patient’s next of kin pays for the test. A PDF file of the result is sent both to the patient’s next of kin and to treating physicians.

This study was approved and consent was waived by the Ethics Committee of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (2023-0157-01). De-identified data comprising of age, gender, date of specimen collection, SARS-CoV-2 reads and fungi from BALF were retrospectively collected from critical care physicians who are working in tertiary hospitals and are acquainted with the authors. Patients with COVID-19 and a result of BALF NGS were included. Except for the first result, patients with more than one BALF NGS result were excluded.

Statistical analysis

Age was presented as mean ± standard deviation, and SARS-CoV-2 reads as median [interquartile range]. Qualitative data were presented as count (percentage). No comparison or regression was conducted.

Results

From December 13th, 2022 to January 5th, 2023, 960 patients with COVID-19 were included, with one record for each patient and they were from 1 autonomous region, 2 centrally-administered municipalities and 18 provinces of China's mainland.

Gender was unknown in 38 patients, and 648 (70.3%) of the rest patients were male. For 876 patients with information on age, their mean ± standard age was 63.4 ± 21.3 years, with the minimum being 0.2 years and the maximum being 101 years (Table 1). Among these patients, 53 (6.1%) patients were below 18 years, and 521 (59.5) patients no less than 65 years, including 195 (22.3%) no less than 80 years.Table 1 Age and gender of 960 patients included

Demographic information	Calculated values	
Gender (n = 922)		
 Male	648 (70.3%)	
Age (n = 876)		
 Mean ± standard deviation, years	63.4 ± 21.3	
 Minimum, years	0.2	
 Maximum, year	101	
 Age < 18 years	53 (6.1%)	
 Age < 6 years	19 (2.2%)	
 Age < 1	7 (0.8%)	
 Age ≥ 65	521 (59.5%)	
 Age ≥ 80	195 (22.3%)	

For all the patients, their median [interquartile range] SARS-CoV-2 reads were 26,038 [4421.5, 44,641.5]. The Aspergilli were identified in 159 (16.6%) patients, with Aspergillus fumigatus, Aspergillus flavus and Aspergillus niger in 103 (10.7%), 81 (8.4%) and 17 (1.8%), respectively (Table 2). In patients with Aspergillus, Aspergillus fumigatus was identified in 64.8% of patients, and Aspergillus flavus in 50.9%. Two Aspergillus species were identified in 38 (4.0%) patients, and three in 7 (0.7%) patients. The Mucoraceae were identified in 14 (1.5%) patients, with Rhizopus in 12 (1.3%) and Rhizomucor in 3 (0.3%) patients. Two Mucoraceae species were identified in 1 patient. Both species of Aspergillus and Mucoraceae were identified in 11 (1.1%) patients. Pneumocystis jirovecii was identified in 65 (6.8%) patients, among whom 12 (18.5%) patients concomitantly had Aspergilli. The Cryptococcaceae and the Dematiaceae were also identified in some patients, including Cryptococcus in 11 (1.1%) patients (Table 2).Table 2 Fungi identified by next-generation sequencing in BALF from 960 patients with COVID-19

Family/genus/species of fungi from BALF	Number of patients (%)	
Moniliaceae	159 (16.6%)	
 Aspergillus	159 (16.6%)	
  Aspergillus fumigatus	103 (10.7%)	
   Aspergillus flavus	81 (8.4%)	
   Aspergillus niger	17 (1.8%)	
   Aspergillus terreus	7 (0.7%)	
   Aspergillus hominis	2 (0.2%)	
   Aspergillus tubingenensis	1 (0.1%)	
Mucoraceae	14 (1.5%)	
 Rhizopus	12 (1.3%)	
  Rhizopus oryzae	7 (0.7%)	
  Rhizopus microspores	5 (0.5%)	
 Rhizomucor	3 (0.3%)	
  Rhizomucor pusillus	3 (0.3%)	
Pneumocystidaceae	65 (6.8%)	
 Pneumocystis		
  Pneumocystis jirovecii	65 (6.8%)	
Cryptococcaceae	14 (1.5%)	
 Trichosporon		
  Trichosporon asahii	3 (0.3%)	
 Cryptococcus		
  Cryptococcus neoformans	11 (1.1%)	
Dematiaceae	1 (0.1%)	
 Exophiala		
  Exophiala dermatitidis	1 (0.1%)	
 Candida	381 (39.7%)	
  Candida albicans	303 (31.6%)	
  Candida tropicalis	58 (6.0%)	
  Candida krusei	11 (1.2%)	
  Candida glabrata	86 (9.0%)	
  Candida parapsilosis	1 (0.1%)	
COVID-19 coronavirus disease 2019, BALF bronchoalveolar lavage fluid

Discussion

As far as we know, our study was the first large sample-sized one depicting fungi identified by next-generation sequencing in BALF among patients with COVID-19. Different families of fungi, including Moniliaceae, Mucoraceae, Pneumocystidaceae, and Cryptococcaceae were identified.

Most fungi are opportunistic pathogenic microorganisms, but invasive fungal infection (IFI) complicates the clinical course of critically ill patients and is life-threatening [1]. Respiratory viruses, like influenza and SARS-CoV-2, damage the respiratory system directly, facilitating fungal infection in both immunocompromised and non-immunocompromised patients [3]. Furthermore, SARS-CoV-2 causes a decrease of T-cell, especially in critically ill patients [4]. Treating COVID-19 with dexamethasone and IL-6 receptor antagonists is beneficial in some patients, but is detrimental in other patients, leading to superinfections [3].

IFI is time-sensitive and should be treated promptly, but its timely diagnosis is hard to reach. Generally, host factors, clinical factors (especially radiological findings), and microbiological evidence are used to diagnose fungal infection. IPA is associated with impaired immune function due to neutropenia, hematological or oncological malignancy, stem cell or solid organ transplantation, prolonged use of corticosteroids, immunosuppressive or cytotoxic treatment, and inborn or acquired immunodeficiency [1, 3]. Besides these immunosuppressive conditions, mucormycosis is also associated with poorly controlled diabetes mellitus and malnutrition [5]. Due to a high prevalence of SARS-CoV-2 infection, many critically ill patients with COVID-19 lack those host factors. Radiological presentations in patients with COVID-19 are manifold and non-specific, resembling those of IPA and probably overshadowing those of IPA from non-COVID-19 patients with typical host factors. Mucormycosis begins with the inhalation of sporangiospores ubiquitous in the environment. During mechanical ventilation, sporangiospores could go directly into lungs. In spontaneous breathing patients, sporangiospores infect the nasal turbinates, and invade hard palate, paranasal sinuses, orbit, and brain. Besides pulmonary involvement, the Mucoraceae causes rhino-orbital and cerebral damages aggressively [6, 7].

The gold standard in the confirmation of invasive pulmonary fungal infection is lung biopsy culture and tissue microscopy [1, 3]. The biopsy of infected lungs is a high-risk procedure, which is not always feasible. For one thing, the clinical course of critically ill patients with COVID-19 is usually long-lasting, refuting repeated biopsies. For another, medical resources are overwhelmed in face of the extremely large patient population. Bronchoscopy and BALF are more obtainable than lung biopsies and are considered as best alternatives. Positive BALF culture and DNA sequences are used to diagnose IFI. PCR testing of BALF is also used in diagnosing IPA, which is considered at least similarly specific to that of galactomannan testing [1, 8]. However, PCR testing of BALF is not considered a diagnostic criterion by AspICU and BM-Asp ICU [9, 10].

Different families of fungi infect lungs of COVID-19 patients. NGS detects multiple fungi at the same time, while confirming SARS-CoV-2 infection. In a study of non-ARDS and non-COVID-19 patients, Zhan et al. found that in 28 BALF NGS Aspergillus-positive traditional immunocompromised patients, 23 (82.1%) patients met the diagnosis of IPA using European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria [11]. As far as we know, the test performance of BALF NGS in critically ill COVID-19 patients has not been studied. Whether BALF NGS results should be incorporated into the diagnosis of IFI in different patient populations needs further exploration.

Some findings are worth noting. The prevalence of Aspergilli identified in our study was 16.6%, which is similar to proven and probable COVID-19-associated pulmonary aspergillosis from a previous study. During the first wave of SARS-CoV-2 infection, Gangneux et al. found that 76 (15%) patients met the European Confederation of Medical Mycology and International Society for Human and Animal Mycology criteria for proven and probable pulmonary aspergillosis in mechanically ventilated COVID-19 patients [12]. Aspergillus fumigatus constitutes 68% of Aspergillus species identified in BALF, which is almost identical to 66% reported by Apostolopoulou et al. [13]. However, the proportion of Aspergillus flavus is much higher in our study. The prevalence of mucormycosis in critical patients with COVID-19 in ICUs was 0.3%-0.8% [14]. During the second wave of COVID-19 epidemic in India, mucormycosis surged [11]. In accordance with previous studies, genus Rhizopus is the most commonly identified in humans [15, 16].

Another interesting finding of our study is that Pneumocystis jirovecii was identified in 65 (6.8%) patients. Bretagne et al. found that in 244 patients with COVID-19 from intensive care units, Pneumocystis jirovecii was identified in 17 (7.0%) patients using PCR assays, and 10 (58.8%) were immunosuppressive [17]. Alanio et al. found that Pneumocystis jirovecii PCR was positive in 10 of 108 (9.3%) critically ill HIV-negative COVID-19 patients, 4 of these 10 patients were given a prophylactic regimen of co-trimoxazole and EORTC/MSG criteria of IPA fulfilled in 5 of these 10 patients [18]. The mortality of Pneumocystis jirovecii positive critically ill patients with COVID-19 was about 30% in both studies, which is lower than that of patients with IPA [17, 18].

Cryptococcus was identified in 11 (1.1%) patients in our study. Cryptococcus can infect blood, lung and meninges concurrently or after recovery in immunocompromised or immunocompetent patients with COVID-19, and the infection may also disseminate [19]. The clinical and radiological presentations of COVID-19 may also overshadow those of Cryptococcus infection, leading to the under-recognition of Cryptococcus pulmonary infection. [20] Although the findings of Candida were also presented in Table 2, Candida airway colonization is common in critically ill patients with COVID-19, but Candida pneumonia is rare [12, 17, 20].

This study has several limitations. First, the clinical course and prognosis were unavailable. Second, past medical history and laboratory test results were unavailable, making it hard to interpret the relationship among fungal findings, SARS-CoV-2 infection and preceding immune conditions. Third, although we believe most if not all of BALF in this study was obtained in mechanically ventilated critically ill patients, we cannot prove it. Fourth, the results from different NGS companies were retrospectively used, and NGS workflows may differ. Fifth, false-positive next-generation sequencing (NGS) results can occur [21]. Contamination occurs as common microbial cultures. Environmental contamination usually comes from the air in the room. Other sources of contamination include the specimen container, the bronchoscope, handling of BALF samples or even the reagents used. Secretions from the upper respiratory tract can transfer colonized microorganisms to the lower respiratory tract, which can then be detected by NGS.

Conclusions

In bronchoalveolar lavage fluid among patients with COVID-19, the Aspergilli were very commonly identified, as were the Mucoraceae, Pneumocystis jirovecii and Cryptococcus via next-generation sequencing.

Abbreviations

BALF Bronchoalveolar lavage fluid

COVID-19 Coronavirus disease 2019

EORTC/MSG European Organization for Research and Treatment of Cancer/Mycoses Study Group

ICU Intensive care unit

IFI Invasive fungal infection

IPA Invasive pulmonary aspergillosis

NGS Next-generation sequencing

Acknowledgements

We acknowledge all people involving caring for COVID-19 patients, and all the patients and their families, from whom the data of this study were acquired.

Author contributions

XY, XG, and YS designed the study. XG, JX, and YS contributed to the implementation of the study and data collection. XY, XG, and HZ wrote and revised the manuscript. All authors read and approved the final manuscript.

Funding

National Key Research and Development program from Ministry of Science and Technology of the People's Republic of China (2021YFC2500801).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The study was conducted in accordance with the declaration of Helsinki and national and institutional standards. This study was approved and consent was waived by the Ethics Committee of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (2023-0157-01).

Consent for publication

Not applicable.

Competing interests

The authors had an experience collaborating with NGS companies to identify pathogens while treating critically ill patients. All authors declare that they have no other competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Koehler P Bassetti M Chakrabarti A Chen SCA Colombo AL Hoenigl M Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance Lancet Infect Dis 2021 21 e149 e162 33333012
Koehler P, Bassetti M, Chakrabarti A, Chen SCA, Colombo AL, Hoenigl M, et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. 2021;21:e149–62.33333012
2. Patterson TF Thompson GR 3rd Denning DW Fishman JA Hadley S Herbrecht R Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America Clin Infect Dis 2016 63 e1 60 27365388
Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63:e1-60.27365388
3. Hoenigl M Seidel D Sprute R Cunha C Oliverio M Goldman GH COVID-19-associated fungal infections Nat Microbiol 2022 7 1127 1140 35918423
Hoenigl M, Seidel D, Sprute R, Cunha C, Oliverio M, Goldman GH, et al. COVID-19-associated fungal infections. Nat Microbiol. 2022;7:1127–40.35918423
4. Diao B Wang C Tan Y Chen X Liu Y Ning L Reduction and functional exhaustion of T cells in patients with Coronavirus Disease 2019 (COVID-19) Front Immunol 2020 11 827 32425950
Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and functional exhaustion of T cells in patients with Coronavirus Disease 2019 (COVID-19). Front Immunol. 2020;11:827.32425950
5. Cornely OA Alastruey-Izquierdo A Arenz D Chen SCA Dannaoui E Hochhegger B Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium Lancet Infect Dis 2019 19 e405 e421 31699664
Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19:e405–21.31699664
6. Casalini G Giacomelli A Ridolfo A Gervasoni C Antinori S Invasive fungal infections complicating covid-19: a narrative review J Fungi 2021 7 921
Casalini G, Giacomelli A, Ridolfo A, Gervasoni C, Antinori S. Invasive fungal infections complicating covid-19: a narrative review. J Fungi. 2021;7:921.
7. Spellberg B Edwards JJ Ibrahim A Novel perspectives on mucormycosis: pathophysiology, presentation, and management Clin Microbiol Rev 2005 18 556 569 16020690
Spellberg B, Edwards JJ, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18:556–69.16020690
8. White PL Wingard JR Bretagne S Löffler J Patterson TF Slavin MA Aspergillus polymerase chain reaction: systematic review of evidence for clinical use in comparison with antigen testing Clin Infect Dis 2015 61 1293 1303 26113653
White PL, Wingard JR, Bretagne S, Löffler J, Patterson TF, Slavin MA, et al. Aspergillus polymerase chain reaction: systematic review of evidence for clinical use in comparison with antigen testing. Clin Infect Dis. 2015;61:1293–303.26113653
9. Blot SI Taccone FS Van den Abeele A-M Bulpa P Meersseman W Brusselaers N A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients Am J Respir Crit Care Med 2012 186 56 64 22517788
Blot SI, Taccone FS, Van den Abeele A-M, Bulpa P, Meersseman W, Brusselaers N, et al. A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med. 2012;186:56–64.22517788
10. Hamam J Navellou J-C Bellanger A-P Bretagne S Winiszewski H Scherer E New clinical algorithm including fungal biomarkers to better diagnose probable invasive pulmonary aspergillosis in ICU Ann Intensive Care 2021 11 41 33683480
Hamam J, Navellou J-C, Bellanger A-P, Bretagne S, Winiszewski H, Scherer E, et al. New clinical algorithm including fungal biomarkers to better diagnose probable invasive pulmonary aspergillosis in ICU. Ann Intensive Care. 2021;11:41.33683480
11. Zhan W Liu Q Yang C Zhao Z Yang L Wang Y Evaluation of metagenomic next-generation sequencing diagnosis for invasive pulmonary aspergillosis in immunocompromised and immunocompetent patients Mycoses 2022 66 331 337
Zhan W, Liu Q, Yang C, Zhao Z, Yang L, Wang Y, et al. Evaluation of metagenomic next-generation sequencing diagnosis for invasive pulmonary aspergillosis in immunocompromised and immunocompetent patients. Mycoses. 2022;66:331–7.
12. Gangneux J-P Dannaoui E Fekkar A Luyt C-E Botterel F De Prost N Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study Lancet Respir Med 2022 10 180 190 34843666
Gangneux J-P, Dannaoui E, Fekkar A, Luyt C-E, Botterel F, De Prost N, et al. Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study. Lancet Respir Med. 2022;10:180–90.34843666
13. Apostolopoulou A Esquer Garrigos Z Vijayvargiya P Lerner AH Farmakiotis D Invasive pulmonary aspergillosis in patients with SARS-CoV-2 infection: a systematic review of the literature Diagnostics (Basel) 2020 10 807 33050499
Apostolopoulou A, Esquer Garrigos Z, Vijayvargiya P, Lerner AH, Farmakiotis D. Invasive pulmonary aspergillosis in patients with SARS-CoV-2 infection: a systematic review of the literature. Diagnostics (Basel). 2020;10:807.33050499
14. Hoenigl M Seidel D Carvalho A Rudramurthy SM Arastehfar A Gangneux J-P The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries Lancet Microbe 2022 3 e543 e552 35098179
Hoenigl M, Seidel D, Carvalho A, Rudramurthy SM, Arastehfar A, Gangneux J-P, et al. The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe. 2022;3:e543–52.35098179
15. Lee FY Mossad SB Adal KA Pulmonary mucormycosis: the last 30 years Arch Intern Med 1999 159 1301 1309 10386506
Lee FY, Mossad SB, Adal KA. Pulmonary mucormycosis: the last 30 years. Arch Intern Med. 1999;159:1301–9.10386506
16. Borkar SG Mucormycosis: a surge in Mucorales fungal infection in post-Covid patients in Indian states and insight into known and unknown factors Int J Glob Health 2021 1 26 60
Borkar SG. Mucormycosis: a surge in Mucorales fungal infection in post-Covid patients in Indian states and insight into known and unknown factors. Int J Glob Health. 2021;1:26–60.
17. Bretagne S Sitbon K Botterel F Dellière S Letscher-Bru V Chouaki T COVID-19-associated pulmonary aspergillosis, fungemia, and pneumocystosis in the intensive care unit: a retrospective multicenter observational cohort during the first French pandemic wave Microbiol Spectr 2021 9 e0113821 34668768
Bretagne S, Sitbon K, Botterel F, Dellière S, Letscher-Bru V, Chouaki T, et al. COVID-19-associated pulmonary aspergillosis, fungemia, and pneumocystosis in the intensive care unit: a retrospective multicenter observational cohort during the first French pandemic wave. Microbiol Spectr. 2021;9: e0113821.34668768
18. Alanio A Dellière S Voicu S Bretagne S Mégarbane B The presence of Pneumocystis jirovecii in critically ill patients with COVID-19 J Infect 2021 82 84 123 33157150
Alanio A, Dellière S, Voicu S, Bretagne S, Mégarbane B. The presence of Pneumocystis jirovecii in critically ill patients with COVID-19. J Infect. 2021;82:84–123.33157150
19. Passerini M Terzi R Piscaglia M Passerini S Piconi S Disseminated cryptococcosis in a patient with metastatic prostate cancer who died in the Coronavirus Disease 2019 (COVID-19) outbreak Cureus 2020 12 e8254 32596073
Passerini M, Terzi R, Piscaglia M, Passerini S, Piconi S. Disseminated cryptococcosis in a patient with metastatic prostate cancer who died in the Coronavirus Disease 2019 (COVID-19) outbreak. Cureus. 2020;12: e8254.32596073
20. Basile K Halliday C Kok J Chen SC-A Fungal infections other than invasive aspergillosis in COVID-19 patients J Fungi (Basel). 2022 8 58 35049999
Basile K, Halliday C, Kok J, Chen SC-A. Fungal infections other than invasive aspergillosis in COVID-19 patients. J Fungi (Basel). 2022;8:58.35049999
21. Wang J Ye J Yang L Chen X Fang H Liu Z Inconsistency analysis between metagenomic next-generation sequencing results of cerebrospinal fluid and clinical diagnosis with suspected central nervous system infection BMC Infect Dis 2022 22 764 36180859
Wang J, Ye J, Yang L, Chen X, Fang H, Liu Z, et al. Inconsistency analysis between metagenomic next-generation sequencing results of cerebrospinal fluid and clinical diagnosis with suspected central nervous system infection. BMC Infect Dis. 2022;22:764.36180859
